• Search History (Register)
  • MeSH Browser
  • [Clear]
    • English

Welcome to the international HTA database


Showing [17111 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2017     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Endobronchial valves for the treatment of emphysema bullae.
2017     National Institute for Health and Care Excellence (NICE) Cetuximab and panitumumab for previously untreated metastatic colorectal cancer. NICE technology appraisal guidance 439
2017     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Barricaid prosthesis for partial annulus replacement
2017     National Institute for Health and Care Excellence (NICE) Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine. NICE technology appraisal guidance 440
2017     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Endovascular arteriovenous fistula creation systems
2017     National Institute for Health and Care Excellence (NICE) Ixekizumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 442
2017     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) STAR tumour ablation system
2017     National Institute for Health and Care Excellence (NICE) Obeticholic acid for treating primary biliary cholangitis. NICE technology appraisal guidance 443
2017     NIHR Health Technology Assessment programme Effectiveness and cost effectiveness of cognitive behaviour therapy and short-term psychoanalytic psychotherapy compared with brief psychosocial intervention in the maintenance of symptomatic remission in adolescents with unipolar major depression (IMPACT): a randomised controlled trial
2017     National Institute for Health and Care Excellence (NICE) Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 444
2017     National Institute for Health and Care Excellence (NICE) Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 445
2017     National Institute for Health and Care Excellence (NICE) Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia. NICE technology appraisal guidance 450
2017     National Institute for Health and Care Excellence (NICE) Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia. NICE technology appraisal guidance 451
2017     National Institute for Health and Care Excellence (NICE) Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal). NICE technology appraisal guidance 452
2017     NIHR Health Technology Assessment programme Support and Assessment for Fall Emergency Referrals (SAFER) 2: a cluster randomised trial and systematic review of clinical effectiveness and cost-effectiveness of new protocols for emergency ambulance paramedics to assess older people following a fall with referral to community-based care when appropriate
2017     National Institute for Health and Care Excellence (NICE) Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal). NICE technology appraisal guidance 453
2017     National Institute for Health and Care Excellence (NICE) Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 454
2017     HAYES, Inc. Dorsal root ganglion stimulation for the treatment of complex regional pain syndrome
2017     National Institute for Health and Care Excellence (NICE) Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people. NICE technology appraisal guidance 455
2017     HAYES, Inc. Flexitouch system (Tactile Systems Technology Inc.) for lymphedema
2017     National Institute for Health and Care Excellence (NICE) Ustekinumab for moderately to severely active Crohn's disease after previous treatment. NICE technology appraisal guidance 456
2017     HAYES, Inc. Glucagon-like peptide-1 receptor agonists for the treatment of obesity in women with polycystic ovary syndrome
2017     National Institute for Health and Care Excellence (NICE) Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane. NICE technology appraisal guidance 458
2017     HAYES, Inc. iFuse Implant System (SI-Bone Inc.) for sacroiliac joint fusion for treatment of sacroiliac joint dysfunction
2017     National Institute for Health and Care Excellence (NICE) Adalimumab and dexamethasone for treating non-infectious uveitis. NICE technology appraisal guidance 460
2017     HAYES, Inc. Gore cardioform septal occluder (W.L. Gore & Associates) for closure of atrial septal defects
2017     National Institute for Health and Care Excellence (NICE) Roflumilast for treating chronic obstructive pulmonary disease. NICE technology appraisal guidance 461
2017     HAYES, Inc. Impella 2.5 System (Abiomed Inc.) for cardiac support in patients undergoing high-risk percutaneous coronary intervention
2017     National Institute for Health and Care Excellence (NICE) Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma. NICE technology appraisal guidance 462
2017     HAYES, Inc. Intravenous immunoglobulin for treatment of intractable epilepsy in pediatric patients
2017     National Institute for Health and Care Excellence (NICE) Bisphosphonates for treating osteoporosis. NICE technology appraisal guidance 464
2017     HAYES, Inc. Ketamine infusion for treatment-resistant bipolar depression
2017     National Institute for Health and Care Excellence (NICE) Baricitinib for moderate to severe rheumatoid arthritis. NICE technology appraisal guidance 466
2017     HAYES, Inc. Micra transcatheter pacing system (Medtronic Inc.) for single-chamber pacemaker indications
2017     National Institute for Health and Care Excellence (NICE) Holoclar for treating limbal stem cell deficiency after eye burns. NICE technology appraisal guidance 467
2017     NIHR Health Technology Assessment programme The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysis
2017     HAYES, Inc. Ocrelizumab (Ocrevus; Genentech Inc.) for primary progressive and relapsing-remitting multiple sclerosis
2017     National Institute for Health and Care Excellence (NICE) Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal). NICE technology appraisal guidance 468
2017     HAYES, Inc. Radiofrequency nerve ablation for treatment of plantar fasciitis
2017     National Institute for Health and Care Excellence (NICE) Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal). NICE technology appraisal guidance 469
2017     NIHR Public Health Research (PHR) programme Evaluation of the impacts on health of the proposed UK industry levy on sugar sweetened beverages: developing a systems map and data platform, and collection of baseline and early impact data
2017     HAYES, Inc. Raindrop near vision inlay (ReVision Optics Inc.) for presbyopia
2017     National Institute for Health and Care Excellence (NICE) Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck. NICE technology appraisal guidance 473
2017     HAYES, Inc. Teduglutide (Gattex; Shire-NPS Pharmaceuticals Inc.) to reduce parenteral support requirements in adults with short bowel syndrome
2017     National Institute for Health and Care Excellence (NICE) Sorafenib for treating advanced hepatocellular carcinoma. NICE technology appraisal guidance 474
2017     HAYES, Inc. Urolift system (NeoTract Inc.) for treatment of benign prostatic hyperplasia
2017     National Institute for Health and Care Excellence (NICE) Dimethyl fumarate for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 475
2017     NIHR Health Technology Assessment programme The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation
2017     HAYES, Inc. Afirma thyroid FNA analysis (Veracyte)
2017     National Institute for Health and Care Excellence (NICE) Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer. NICE technology appraisal guidance 476
2017     HAYES, Inc. AlloSure (CareDx)
2017     National Institute for Health and Care Excellence (NICE) Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma. NICE technology appraisal guidance 478
2017     HAYES, Inc. Cologuard (Exact Sciences Corp.)
2017     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: chemoembolization for unresectable liver metastases according to the primary origin and chemoperfusion for advanced pancreatic cancer]
2017     National Institute for Health and Care Excellence (NICE) Reslizumab for treating severe eosinophilic asthma. NICE technology appraisal guidance 479
2017     HAYES, Inc. GeneStrat (Biodesix Inc.)
2017     National Institute for Health and Care Excellence (NICE) Tofacitinib for moderate to severe rheumatoid arthritis. NICE technology appraisal guidance 480
2017     HAYES, Inc. OVA1 (ASPiRA Labs)
2017     National Institute for Health and Care Excellence (NICE) Immunosuppressive therapy for kidney transplant in adults. NICE technology appraisal guidance 481
2017     HAYES, Inc. ThyGenX and ThyraMIR (Interpace Diagnostics)
2017     National Institute for Health and Care Excellence (NICE) Immunosuppressive therapy for kidney transplant in children and young people. NICE technology appraisal guidance 482
2017     HAYES, Inc. Comparative effectiveness of bioresorbable vascular scaffold stents versus other drug-eluting stents for the treatment of coronary artery disease
2017     National Institute for Health and Care Excellence (NICE) Sarilumab for moderate to severe rheumatoid arthritis. NICE technology appraisal guidance 485
2017     HAYES, Inc. Comparative effectiveness of endovenous radiofrequency ablation versus conventional surgery for symptomatic varicose veins: a review of reviews
2017     National Institute for Health and Care Excellence (NICE) Aflibercept for treating choroidal neovascularisation. NICE technology appraisal guidance 486
2017     NIHR Health Technology Assessment programme Managing diabetes in people with dementia: a realist review
2017     HAYES, Inc. Comparative effectiveness of skin substitutes for chronic foot ulcers in adults with diabetes mellitus: a review of reviews
2017     National Institute for Health and Care Excellence (NICE) Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours. NICE technology appraisal guidance 488
2017     HAYES, Inc. Comparative effectiveness of skin substitutes for chronic venous leg ulcers in adults: a review of reviews
2017     National Institute for Health and Care Excellence (NICE) Vismodegib for treating basal cell carcinoma. NICE technology appraisal guidance 489
2017     HAYES, Inc. Comparative effectiveness review of antimicrobial versus conventional sutures
2017     National Institute for Health and Care Excellence (NICE) Naltrexone–bupropion for managing overweight and obesity. NICE technology appraisal guidance 494
2017     NIHR Health Technology Assessment programme Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia
2017     HAYES, Inc. Comparative effectiveness review of endoscopic therapy for gastroesophageal reflux disease
2017     National Institute for Health and Care Excellence (NICE) Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. NICE technology appraisal guidance 496
2017     NIHR Health Technology Assessment programme The clinical effectiveness of different surveillance strategies to prevent colorectal cancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations
2017     HAYES, Inc. Comparative effectiveness review of hyaluronic acid for knee osteoarthritis: a review of reviews
2017     HAYES, Inc. Comparative effectiveness review of minimally invasive total hip arthroplasty
2017     Norwegian Institute of Public Health (NIPH) Assessment of conductive education for children and adolescents with brain damage: a health technology assessment
2017     HAYES, Inc. Comparative effectiveness review of multilevel artificial disc replacement for cervical degenerative disc disease
2017     Norwegian Institute of Public Health (NIPH) Digital Breast Tomosynthesis with Hologic 3D mammography Selenia Dimensions System for use in breast cancer screening
2017     HAYES, Inc. Comparative effectiveness review of nonirradiated allografts for primary anterior cruciate ligament reconstruction
2017     Norwegian Institute of Public Health (NIPH) Sutureless aortic valve replacement for treatment of severe aortic stenosis: A single technology assessment of Perceval sutureless aortic valve
2017     HAYES, Inc. Comparative effectiveness review of platelet-rich plasma for knee osteoarthritis: a review of reviews
2017     Norwegian Institute of Public Health (NIPH) FreeStyle Libre Flash Glucose Self-Monitoring System: A Single-Technology Assessment
2017     NIHR Health Technology Assessment programme Researching outcomes from forensic services for people with intellectual or developmental disabilities: a systematic review, evidence synthesis and expert and patient/carer consultation
2017     HAYES, Inc. Comparative effectiveness review of platelet-rich plasma for tendinopathies or ligament injuries of the knee
2017     Norwegian Institute of Public Health (NIPH) Assessment of four intensive habilitation programs for children and adolescents with brain damage – a health technology assessment
2017     HAYES, Inc. Comparative effectiveness review of platelet-rich plasma for treatment of lateral epicondylitis: a review of reviews
2017     HAYES, Inc. Comparative effectiveness review of pyrocarbon proximal interphalangeal and metacarpophalangeal joint implants
2017     NIHR Health Technology Assessment programme Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness
2017     HAYES, Inc. Comparative effectiveness review of total ankle replacement: a review of reviews
2017     HAYES, Inc. Digital breast tomosynthesis for breast cancer diagnosis and screening
2017     HAYES, Inc. Functional electrical stimulation for rehabilitation following spinal cord injury
2017     HAYES, Inc. Hyperbaric oxygen therapy for diabetes-related foot ulcers: a review of reviews
2017     National Institute for Health and Care Excellence (NICE) Endobronchial valve insertion to reduce lung volume in emphysema. NICE interventional procedures guidance 600
2017     NIHR Health Technology Assessment programme A multicentre, randomised controlled trial of position during the late stages of labour in nulliparous women with an epidural: clinical effectiveness and an economic evaluation (BUMPES)
2017     NIHR Health Technology Assessment programme A multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin compared with standard therapy for the treatment of transverse myelitis in adults and children (STRIVE)
2017     HAYES, Inc. Impact of preoperative supervised weight loss programs on bariatric surgery outcomes
2017     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Obstetric MRI